soul trial oral semaglutide cardiovascular outcomes 2024 2025 results π§Ώ is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM PDF) Oral Semaglutide and Cardiovascular
Pay in 4 interest-free payments of $6.38 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 25 - Aug 30




















00459-9/asset/824250b9-1540-487f-bf69-9a6850796867/main.assets/gr1_lrg.jpg)






